文献速递消化道出血消化内镜

胶囊内镜检查前使用泻药肠道准备临床价值的多中心盲法随机对照试验

Clinical utility of purgative bowel preparation before capsule endoscopy: a multicenter, blinded, randomized controlled trial.
PubMed 文献 · Gastrointest Endosc · 2022-07-16

该多中心盲法随机对照试验将疑似小肠出血患者随机分为三组:仅清流质组、清流质加2升聚乙二醇组、清流质加1升聚乙二醇与抗坏血酸钠组,比较诊断率、小肠可视化质量和耐受性。结果显示三组P2病变诊断率无显著差异,小肠可视化质量相似,但仅清流质组耐受性更好,提示胶囊内镜前使用泻药肠道准备未改善诊断率或小肠可视化且耐受性更低。

要点

  • 三组P2病变诊断率分别为48.7%、48.0%和45.9%,无显著差异(P = .94)。
  • 三组总体及远端小肠可视化质量相似(P = .94和P = .68)。
  • 仅清流质组耐受性评分1.5,优于2升聚乙二醇组的3.5和1升聚乙二醇加抗坏血酸钠组的2.6(P < .001)。

核心结论

  • 胶囊内镜前使用泻药肠道准备未改善诊断率或小肠可视化质量,且与患者耐受性降低相关。

研究设计与样本

  • 多中心、盲法、随机对照试验,纳入疑似小肠出血患者,共229例完成研究。
  • 患者随机分为三组:A组检查前18小时仅清流质,检查前即刻服西甲硅油200 mg溶于150 mL水;B组同A组加检查前12小时服2升聚乙二醇;C组同A组加检查前3小时服1升聚乙二醇与抗坏血酸钠。
  • 病变按高度相关(P2)或低相关(P0或P1)分类评估诊断率,小肠可视化质量采用Brotz评分,患者耐受性采用视觉模拟量表(0-10分,评分越低耐受性越好)。

主要发现

  • A、B、C三组P2病变诊断率分别为48.7%、48.0%和45.9%,无显著差异(P = .94)。
  • 三组总体小肠可视化质量和远端小肠可视化质量相似(P = .94和P = .68)。
  • A组耐受性平均评分1.5,优于B组的3.5和C组的2.6(P < .001)。
  • 患者平均年龄58.7岁(95%CI 29.3-87.9),男性占47.2%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Optimal bowel preparation before capsule endoscopy (CE) is currently unknown. In this multicenter, blinded, randomized controlled trial, we assessed clinical effectiveness of 2 types of purgative regimen and a control arm of clear fluid only. METHODS: Patients with suspected small intestinal bleeding were randomized into 3 arms: arm A, clear fluids only for 18 hours before CE and simethicone 200 mg in 150 mL water immediately before CE; arm B, same as A + 2 L of polyethylene glycol (PEG) 12 hours before CE; and arm C, same as A + 1 L PEG + sodium ascorbate 3 hours before CE. To assess diagnostic yield, lesions were classified either as highly relevant (P2) or less relevant (P0 or P1) lesions. Small-bowel visualization quality (SBVQ) was assessed using the Brotz score. Patient tolerability was assessed using the visual analog scale (0-10, with lower scores indicating better tolerability). RESULTS: Two hundred twenty-nine patients completed the study. The mean age was 58.7 years (95% confidence interval, 29.3-87.9), and 47.2% were men. There was no significant difference in diagnosis of P2 lesions in arms A, B, and C (48.7%, 48.0%, and 45.9%, respectively; P = .94). Overall SBVQ and distal SBVQ were similar across the 3 arms (P = .94 and P = .68, respectively). Patients reported better tolerability in arm A (mean score, 1.5) compared with arms B and C (mean score, 3.5 and 2.6, respectively; P < .001). CONCLUSIONS: The use of a purgative bowel preparation before CE does not improve diagnostic yield or small-bowel visualization and is associated with lower patient tolerance. (Clinical trial registration number: ACTRN 12614000883617.).

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Lamba M, Ryan K, Hwang J, et al. Clinical utility of purgative bowel preparation before capsule endoscopy: a multicenter, blinded, randomized controlled trial. Gastrointest Endosc. 2022. PMID: 35843287. doi:10.1016/j.gie.2022.07.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。